Mercia Technologies PLC £3.8million syndicated investment into Medherant (8835Y)

TIDMMERC

RNS Number : 8835Y

Mercia Technologies PLC

11 December 2017

 
 RNS              11 December 2017 
 

Mercia Technologies PLC

("Mercia" or the "Group")

Mercia invests GBP2.5million as part of GBP3.8million funding round in Medherant

Mercia Technologies PLC (AIM: MERC), the national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions, is pleased to announce that it has invested GBP2.5million as part of a GBP3.8million funding round in Medherant Limited ("Medherant"), a University of Warwick spinout company developing an innovative transdermal drug delivery patch technology.

Mercia's investment in this significant funding round is alongside both private investors and other current shareholders. The Group's direct equity shareholding has now risen from 11.3% to 32.4%. This new funding will support Medherant as it moves into clinical development and the commercialisation of its ibuprofen TEPI Patch(R), as well as initiating development of its second product, a lidocaine TEPI Patch(R).

Medherant's TEPI Patch(R) is a novel proprietary platform capable of delivering higher doses of drugs through the skin to act locally or systemically. Transdermal delivery has many advantages, including fewer side effects, improved patient compliance and the potential to deliver drugs that are unsuitable for oral administration.

Since Mercia's first investment in June 2015 through its managed funds, Medherant has secured an exclusive licence agreement with Bostik SA, a leading adhesive specialist, to use its novel pressure sensitive adhesive material in the development of the company's TEPI Patch(R).

Nigel Davis, CEO of Medherant, said: "We are grateful to have the continued financial support of Mercia and pleased to be working closely with the team as we move into the next exciting phase of Medherant's development. Our TEPI Patch(R) technology is generating global interest and we are now working with several leading pharmaceutical companies as we develop our own product pipeline."

Mark Payton, Chief Executive Officer at Mercia, said: "Medherant's highly versatile platform is compatible with a wide range of drugs, enabling a transdermal route to market for drugs not currently suitable for formulation with existing delivery technologies. The company's first product, Ibuprofen TEPI Patch(R), will be manufactured at AdhexPharma in France for clinical trials in early 2018. Led by Dr Nicola Broughton, Investment Director and Head of Universities at Mercia, we have been working with the founders since inception, initially through our managed funds and are now scaling the business with a further direct investment. This has increased our equity holding in what potentially may become a very valuable business."

For further information, please contact:

 
Mercia Technologies PLC 
 Mark Payton, Chief Executive Officer 
 Martin Glanfield, Chief Financial Officer     +44 (0)330 
 www.merciatech.co.uk                           223 1430 
Cenkos Securities plc 
 Stephen Keys, Camilla Hume (NOMAD and         +44 (0)20 
 Joint Broker)                                  7397 8900 
 
  Canaccord Genuity Limited 
  Simon Bridges, Emma Gabriel (Joint Broker)     +44 (0)20 
                                                 7523 8000 
  Buchanan 
  Bobby Morse, Victoria Hayns, Chris Lane, 
  Stephanie Watson                               +44 (0)20 
  www.buchanan.uk.com                            7466 5000 
 

About Mercia Technologies PLC

Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow. Mercia Technologies PLC is quoted on AIM with the epic "MERC".

Mercia's 'Complete Capital Solution' initially nurtures businesses via its third party funds (now with circa GBP350.0million under management following recent mandate wins) and then over time Mercia can provide further funding to its 'Emerging Stars' by deploying direct investment follow-on capital from its own balance sheet. Since its IPO in December 2014, Mercia has invested over GBP46.0million directly across its portfolio of 'Emerging Stars'.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMMGZNRKGNZM

(END) Dow Jones Newswires

December 11, 2017 02:00 ET (07:00 GMT)